B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.
B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.